Flexible-Dose Trial in Early Parkinson's Disease (TemPo-2)

  • STATUS
    Recruiting
  • participants needed
    296
  • sponsor
    Cerevel Therapeutics, LLC
Updated on 6 February 2023
dopamine
dopamine agonists
levodopa
dopa
bradykinesia
early parkinson's

Summary

The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

Description

An estimated total of 296 eligible subjects with early Parkinson's Disease, will be randomized to 3 treatment groups.  will be randomized in a 1:1 ratio to receive tavapadon 5 to 15 mg or placebo.  Each subject will participate in the study for approximately 35 weeks including a 30 day screening period, 27 week treatment period, and 4 week follow-up period.

Subjects may continue to an optional open-label extension period for one year.

Details
Condition Parkinson's disease
Treatment Placebo, Tavapadon
Clinical Study IdentifierNCT04223193
SponsorCerevel Therapeutics, LLC
Last Modified on6 February 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note